Search company, investor...
Baxalta company logo


Founded Year



Acq - P2P | Acquired



About Baxalta

Baxalta (NYSE: BXLT) provides bio-pharmaceuticals products. The company offers bio-pharmaceuticals for the treatment of hemophilia, bleeding disorders, immune deficiencies, alpha-1 antitrypsin deficiency, and other chronic. Its therapies are available in many countries. The company was founded in 2015 and is based in Bannockburn, Illinois. In January 2016, Baxalta was acquired by Shire.

Headquarters Location

1200 Lakeside Drive

Bannockburn, Illinois, 60015,

United States


Missing: Baxalta's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Baxalta's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing Baxalta

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Baxalta is included in 2 Expert Collections, including Cancer.



4,784 items

Pharmaceutical and biotechnology companies with cancer therapy drug candidates.


Regenerative Medicine

1,818 items

Regenerative medicine refers to the process of activating, replacing, engineering or regenerating human genetic material, cells, tissues or organs to restore normal function. It also includes bioengineered tissues used for in vitro testing (e.g. organ-on-a-chip, organoids).

Baxalta Patents

Baxalta has filed 258 patents.

The 3 most popular patent topics include:

  • Coagulation system
  • Biotechnology
  • Molecular biology
patents chart

Application Date

Grant Date


Related Topics




Coagulopathies, Coagulation system, Bleeding, Blood tests, Blood


Application Date


Grant Date



Related Topics

Coagulopathies, Coagulation system, Bleeding, Blood tests, Blood



Latest Baxalta News

Takeda claims first phase 3 win in rare disease cTTP

Jan 6, 2023

January 6, 2023 Takeda has reported positive results from a phase 3 trial of its experimental therapy TAK-755 for ultra-rare disease congenital thrombotic thrombocytopenic purpura (cTTP), setting up regulatory filings for the drug. cTTP is a subtype of thrombotic thrombocytopenic purpura (TTP), a rare and life-threatening disorder in which blood clots form in the small blood vessels throughout the body, and is caused by a deficiency in the ADAMTS13 protease enzyme. It is estimated there are fewer than 1,000 patients with the disease in the US. TAK-755 is a recombinant version of the ADAMTS13 protein designed to replace the missing enzyme, which was given in the pivotal study as an intravenous infusion once every week or every other week. Takeda said the drug is the first and only recombinant ADAMTS13 protein in development, and could become a crucial new treatment for patients with cTTP who currently have no therapies approved specifically to manage their condition. At the moment, treatment is the administration of fresh plasma in order to indirectly replenish ADAMTS13 levels in the body and address the symptoms of cTTP, which include haemolytic anaemia, low platelet counts (thrombocytopaenia), and neurological dysfunction. In the phase 3 trial, TAK-755 reduced the incidence of thrombocytopenia events by 60% compared to plasma-based treatment and was much better tolerated, with less than 9% of patients on Takeda’s drug reporting side effects compared to almost half (48%) of those on standard therapy. “The results of the trial are very encouraging, and we look forward to continuing to engage with global regulatory bodies with the aim of bringing TAK-755 to patients as rapidly as possible,” commented Daniel Curran, head of the rare genetics and haematology unit at Takeda. While cTTP represents a tiny patient population for TAK-755, Takeda is also running trials of the drug in other indications, including a phase 2 study in acquired or immune-mediated TTP (iTTP) and phase 1 in sickle cell disease (SCD), which if positive could expand the number of patients eligible for treatment. Approval in iTTP would put TAK-755 in contention with Sanofi’s Cablivi (caplacizumab) which became the first therapeutic specifically indicated for the disease in the US in 2019 and brought in almost $150 million in sales in the first nine months of 2022. Takeda inherited TAK-755 when it completed its acquisition of Shire, which in turn claimed ownership of the drug when it merged with original developer Baxalta in 2016. Don't miss your daily pharmaphorum news.

Baxalta Frequently Asked Questions (FAQ)

  • When was Baxalta founded?

    Baxalta was founded in 2015.

  • Where is Baxalta's headquarters?

    Baxalta's headquarters is located at 1200 Lakeside Drive, Bannockburn.

  • What is Baxalta's latest funding round?

    Baxalta's latest funding round is Acq - P2P.

  • Who are the investors of Baxalta?

    Investors of Baxalta include Shire and Baxter International.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.